Bauerfeind, P; Beglinger, C; Beltinger, J; Braegger, C; Eigenmann, F; Fried, M; Guyot, J; Hürlimann, R; Michetti, P; Seibold, F; Straumann, A (2006). Infliximab - Recommendations practiques pour le traitment de la maladie de Crohn. Revue médicale suisse, 2(74), pp. 1807-15. Genève: Médecine & Hygiène
Full text not available from this repository.Infliximab is a monoclonal chimeric antibody, with high affinity and specificity for tumour necrosis factor alpha (TNFalpha) that plays a central role in the pathogenesis of immune mediated inflammatory disorders including Crohn's disease and ulcerative colitis. Globally over 600000 patients have been treated with infliximab to date. This global experience led to a better definition of the overall safety and efficacy profile of this medication. The goal of the present recommendations is to provide practical information to physicians involved in the care of patients with inflammatory bowel disease.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology |
UniBE Contributor: |
Seibold, Frank Werner |
ISSN: |
0025-6749 |
ISBN: |
16927560 |
Publisher: |
Médecine & Hygiène |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:50 |
Last Modified: |
05 Dec 2022 14:15 |
PubMed ID: |
16927560 |
URI: |
https://boris.unibe.ch/id/eprint/20882 (FactScience: 4676) |
Actions (login required)
 |
Edit item |